Published • loading... • Updated
FDA’s plan to boost biosimilar drugs could stall at the Patent Office
Summary by The Sentinel-Echo
1 Articles
1 Articles
FDA’s plan to boost biosimilar drugs could stall at the Patent Office
While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the cheaper medicines to get on the market, industry…
Coverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
